Medical use of cannabis. Cannabidiol: a new light for schizophrenia ? Serena Deiana Drug Testing and Analysis, 2013, 5, (1), 46-51 doi: 10.1002/dta.1425. Abstract The medical properties of cannabis have been known for many centuries; its first documented use dates back to 2800 BC when it was described for its hallucinogenic and pain-relieving properties. In the first half of the twentieth century, a number of pharmaceutical companies marked cannabis for indications such as asthma and pain, but since then its use has sharply declined, mainly due to its unpredictable effects, but also for socio-political issues. Recently, great attention has been directed to the medical properties [...]
Lire la suiteCannabinoids and Schizophrenia : Risks and Therapeutic Potential Marc W. Manseau & Donald C. Goff Neurotherapeutics, 2015, 12, 816–824 DOI 10.1007/s13311-015-0382-6 # The American Society for Experimental NeuroTherapeutics, Inc. 2015 Abstract A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a [...]
Lire la suiteA Systematic Review on the Pharmacokinetics of Cannabidiol in Humans Sophie A. Millar, Nicole L. Stone, Andrew S. Yates and Saoirse E. O’Sullivan Frontiers in Pharmacology, 26 November 2018 https://doi.org/10.3389/fphar.2018.01365 Background : Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate published data in this area. Methods : A systematic search of PubMed and EMBASE (including MEDLINE) was conducted to retrieve all articles reporting pharmacokinetic data of CBD in humans. Results : Of 792 articles retireved, 24 included [...]
Lire la suiteThe Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis Britta Hahn Schizophrenia Bulletin, 2018, vol. 44, no. 1, 46–53 doi:10.1093/schbul/sbx105 A major factor associated with poor prognostic outcome after a first psychotic break is cannabis misuse, which is prevalent in schizophrenia and particularly common in individuals with recent-onset psychosis. Behavioral interventions aimed at reducing cannabis use have been unsuccessful in this population. Cannabidiol (CBD) is a phytocannabinoid found in cannabis, although at low concentrations in modern-day strains. CBD has a broad pharmacological profile, but contrary to Δ9-tetrahydrocannabinol (THC), CBD does not activate CB1 or CB2 receptors and has at most subtle subjective [...]
Lire la suiteThe Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients : Pilot Study Gil Bar-Sela, Daniela Zalman, Valerya Semenysty and Eyal Ballan Integrative Cancer Therapies, 2019, Volume 18, 1–8 DOI: 10.1177/1534735419881498 Abstract Background : Cancer-related cachexia and anorexia syndrome (CACS) is a common phenomenon in cancer patients. Cannabis has been suggested to stimulate appetite but research on this issue has yielded mixed results. The current study aimed to evaluate the effect of dosage-controlled cannabis capsules on CACS in advanced cancer patients. Methods : The cannabis capsules used in this study contained two fractions of oil-based compounds. The planned treatment was [...]
Lire la suiteCannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1–2 Phosphorylation Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow and Steven R. Laviolette Journal of Neuroscience, 2019, 39, (44), 8762-8777 Doi : https://doi.org/10.1523/JNEUROSCI.0708-19.2019 Abstract Evidence suggests that the phytocannabinoids Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differentially regulate salience attribution and psychiatric risk. The ventral hippocampus (vHipp) relays emotional salience via control of dopamine (DA) neuronal activity states, which are dysregulated in psychosis and schizophrenia. Using in vivo electrophysiology in male Sprague Dawley rats, we demonstrate that intra-vHipp THC strongly increases ventral tegmental area (VTA) DA neuronal frequency [...]
Lire la suitePreclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry Gioacchino Calapai, Carmen Mannucci, Ioanna Chinou, Luigi Cardia, Fabrizio Calapai, Emanuela Elisa Sorbara, Bernardo Firenzuoli, Valdo Ricca, Gian Franco Gensini and Fabio Firenzuoli Hindawi - Evidence-Based Complementary and Alternative Medicine, 2019, Article ID 2509129, 11 pages https://doi.org/10.1155/2019/2509129 Background : Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders. Objective. &e aim of this review is to illustrate the state of art about scientific research and the evidence of effectiveness of CBD [...]
Lire la suiteNeuroanatomical substrates involved in cannabinoid modulation of defensive responses F.A. Moreira, D.C. Aguiar, L.B. Resstel, S.F. Lisboa, A.C. Campos, F.V. Gomes and F.S. Guimaraes Journal of Psychopharmacology, 2012, 26, (1), 40–55 DOI: 10.1177/0269881111400651 Abstract Administration of Cannabis sativa derivatives causes anxiolytic or anxiogenic effects in humans and laboratory animals, depending on the specific compound and dosage used. In agreement with these findings, several studies in the last decade have indicated that the endocannabinoid system modulates neuronal activity in areas involved in defensive responses. The mechanisms of these effects, however, are still not clear. The present review summarizes recent data suggesting that they involve modulation of [...]
Lire la suiteIs cannabidiol an effective treatment for schizophrenia? R. Guinguis, M.I. Ruiz, G. Rada Medwave, 2017, 17, 7, e7010 DOI: 10.5867/medwave.2017.07.7010 Abstract Cannabidiol has recently been proposed as an antipsychotic for schizophrenia. However, its clinical use and safety is controversial. To answer this question, we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We identified six systematic reviews incorporating four primary studies overall, including two randomized trials. We extracted data from the systematic reviews, reanalyzed data from primary studies, conducted a meta-analysis and generated a summary of findings table [...]
Lire la suiteNotes from the Field : Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol — Utah, 2017–2018 Roberta Z. Horth, Barbara Crouch, B. Zane Horowitz, Amelia Prebish, Matthew Slawson, Jennifer McNair, Chris Elsholz, Stephen Gilley, Jenny Robertson, Ilene Risk, Mary Hill, Linnea Fletcher, Wei Hou, Dallin Peterson, Karlee Adams, Dagmar Vitek, Allyn Nakashima, Angela Dunn MMWR / May 25, 2018 / Vol. 67 / No. 20 US Department of Health and Human Services/Centers for Disease Control and Prevention On December 8, 2017, the Utah Poison Control Center (UPCC) notified the Utah Department of Health (UDOH) of reports of emergency department visits associated with reported [...]
Lire la suite